TR-Dizin İndeksli Açık & Kapalı Erişimli Yayınlar

Permanent URI for this communityhttps://hdl.handle.net/11727/10755

Browse

Filters

2019 - 201912020 - 20221

Settings

Author: search.filters.author.Sezgin, Orhansearch.filters.applied.f.language: search.filters.language.eng

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Improvement of Work Productivity and Quality of Life with Anti-Tumor Necrosis Factor Treatment Used in Crohn's Disease in Routine Clinical Practice in Turkey
    (2022) Toruner, Murat; Basaranoglu, Metin; Atug, Ozlen; Senturk, Omer; Akyuz, Filiz; Cekic, Cem; Hamzaoglu, Hulya Over; Tekin, Fatih; Sezgin, Orhan; Akpinar, Hale; Celik, Aykut Ferhat; Tezel, Ahmet; Gokturk, Huseyin Savas; Kav, Taylan; 35678798
    Background: Patients with Crohn's disease experience major deterioration in work productivity and quality of life. We aimed to provide the long-term effects of anti-tumor necrosis factor agents on work productivity and activity impairment and quality of life in patients with Crohn's disease using the Inflammatory Bowel Disease Questionnaire and the Short-Form Health Survey-36. Methods: Patients with Crohn's disease and initiated an anti-tumor necrosis factor treatment were included and followed up for 12 months in this observational study. Results: A total of 106 patients were included in this study, and 64.2% of the patients were males. Mean [+/- standard deviation] age was 36.8 [+/- 10.9] years. At baseline, mostly perianal fistulas [65.7%] were observed [n = 23]. Intestinal stenosis was detected in 34.9% of the patients [n = 37], and most of the stenosis was located in the ileum [70.6%] followed by the colon [20.6%]. Extraintestinal symptoms were observed in 24 patients [22.6%]. Most frequent extraintestinal symptom was arthritis with 71.4% [n = 15]. Mean time from first symptom to initiation of anti-tumor necrosis factor treatment was 6.3 [+/- 5.0] years. Improvements in work productivity and activity impairment scores throughout 12 months were -24.1% [P =.003] for work time missed, -18.0% [P =.006] for impairment at work, -8.5% [P =.160] for overall work impairment, and -17.0% [P <.001] for daily activity impairment. Similarly, significant improvements [P <.001] were detected in all components of the Inflammatory Bowel Disease Questionnaire when compared to baseline. Statistically significant improvements [P <.05] were detected for all components of Short-Form Health Survey-36 except for mental health [P =.095]. Conclusion: Our study indicates the significant improvement in work productivity and activity impairment and quality of life of patients with Crohn's disease who receive long-term anti-tumor necrosis factor treatment.
  • No Thumbnail Available
    Item
    Population-based assessment of gastrointestinal symptoms and diseases: Cappadocia Cohort, Turkey
    (2019) Sezgin, Orhan; Akpinar, Hale; Ozer, Birol; Toruner, Murat; Bal, Kadir; Bor, Serhat; 31854305
    Background/Aims: The aim of this study was to determine the prevalence of symptoms and diseases of the lower and upper gastrointestinal system (GIS) in a population-based sample. Materials and Methods: The cross-sectional cohort study was conducted in Cappadocia cohort comprising the Gulsehir and Avanos districts. The "Gastrointestinal Symptom Questionnaire" was applied to persons over the age of 18 years. Results: The GI Symptom Questionnaire was applied to 3369 subjects, and height and body weight were measured in 2797 consenting subjects. Of the participants, 61% were female and the mean patient age was 50 +/- 15 years. At least one GI symptom was present in 70.6% of the cohort. The most common upper GI symptoms were gastric bloating (31.0%) and heartburn (29.1%). The most common lower GI symptom was abnormal defecation (33.5). The prevalence of upper GIS and lower GIS diseases was 32.7% and 12.9%, respectively, and the prevalence of togetherness of upper and lower GIS diseases was 9.9%. Prevalence of GIS disease was approximately 3 times higher in females (p<0.001). All of the upper and lower GI symptoms and the prevalence of upper GIS disease increased in line with Body mass index (BMI). Conclusion: This first population-based, cross-sectional cohort study revealed that the prevalence of GIS diseases is critically high for optimal public health. Special attention must be paid to these diseases while planning health policies and reimbursements.